ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0309

Efficacy, Safety, Pharmacokinetics and Immunogenicity of Repeated Dosing of GSK3858279 in Patients with Knee Osteoarthritis: A Phase I, Randomized, Double-Blind, Placebo-Controlled Study
Abstract Number: 0310

Implementing an Osteoarthritis Management Program to Deliver Guideline-Driven Care for Knee and Hip Osteoarthritis in a U.S. Academic Health System
Abstract Number: 0311

Heterogeneity and Natural History of Medial Fixed Joint Space Width in Healthy Knees Among Women and Men: Data from Three Large Cohort Studies
Abstract Number: 0312

Frontal Lobe Activation and Gait Alterations During Single- and Dual-task Walking in People with Knee Osteoarthritis: A Functional Near-infrared Spectroscopy Study
Abstract Number: 0313

The Influence of Pain Catastrophizing on Pain and Function After Knee Arthroplasty for Osteoarthritis
Abstract Number: 0314

Lack of Systemic Effects from Intra-articular XT-150 for the Treatment of Moderate to Severe Pain Due to OA of the Knee: Safety Results from a Phase 2 Trial
Abstract Number: 0315

Identification of Calcium Crystals in End-Stage Osteoarthritis with Raman Spectroscopy
Abstract Number: 0316

Relationship of Sensitization to Pain Severity in Patients with Knee Osteoarthritis
Abstract Number: 0317

Long-term Effectiveness of a Lifestyle Program for Osteoarthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial
Abstract Number: 0318

The Association of CT-Detected Intra-Articular Mineralization with MRI-Detected Effusion-Synovitis and Hoffa’s Synovitis in Knee OA: The Multicenter Osteoarthritis Study
Abstract Number: 0319

Knee Flexion Contracture Was Associated with Articular Cartilage Loss in the Central Region but Cartilage Preservation in the Posterior Region of the Tibia: Data from the Osteoarthritis Initiative
Abstract Number: 0320

Feasibility and Acceptability of Geniculate Artery Embolization for the Treatment of Painful Knee Osteoarthritis
Abstract Number: 0321

Use of Proton Pump Inhibitors and Risk of Hip/knee Joint Replacement Among Patients with Osteoarthritis and Rheumatoid Arthritis
Abstract Number: 0322

Validation of NICE Criteria for the Diagnosis of Knee Osteoarthritis
Abstract Number: 0323

A Randomized, Double-blind, Placebo-controlled, Repeat Injection, 52-Week Study to Evaluate the Efficacy and Safety of an Intra-articular Injection (IAI) of CNTX-4975-05 (CNTX) in Subjects with Chronic, Moderate-to-severe Osteoarthritis Knee Pain (MSOAKP) – Study 304

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].